Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Melanoma subtypes, Breslow depth and urgent referral

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise major cutaneous melanoma subtypes, refer suspicious lesions urgently, preserve diagnostic architecture through full-thickness excision biopsy, and interpret Breslow depth as a central staging and management variable.

  • Superficial-spreading melanoma often evolves as an irregular multicoloured macule or plaque; nodular melanoma is elevated, firm and rapidly growing and may be uniformly coloured.
  • Lentigo maligna melanoma develops within a slowly enlarging irregular macule on chronically sun-damaged head or neck; invasion may arise after a prolonged in-situ phase.
  • Acral lentiginous melanoma affects palms, soles or nail units and must be considered in every skin tone; delayed recognition contributes to thicker presentation.
  • Refer a lesion urgently when the weighted seven-point score is 3 or more, dermoscopy suggests melanoma, or strong nodular, acral, nail or ugly-duckling concern exists.
  • The diagnostic standard is complete full-thickness excision biopsy with a narrow clinical margin where feasible, oriented so Breslow depth and ulceration can be measured.
  • Breslow thickness is the vertical distance in millimetres from the top of the granular layer, or ulcer base, to the deepest invasive melanoma cell.
  • Do not confuse diagnostic excision with definitive wide local excision; the latter margin is chosen after histological stage is known.
  • Palpable nodes or systemic symptoms require specialist staging, but a normal node examination does not exclude microscopic spread.

Key red flags

Rapid nodular growth, ulceration, spontaneous bleeding, acral or nail-unit evolution, palpable nodes, neurological or systemic metastatic symptoms, or a lesion scoring 3 or more on the weighted seven-point checklist requires urgent cancer-pathway assessment.

Nodular pattern

A firm elevated lesion grows continuously over weeks to months and may be black, brown, red or skin-coloured.

Acral lentiginous pattern

An irregular palm or sole patch or broad changing longitudinal nail band may extend pigment onto adjacent nail-fold skin.

Nodal or in-transit disease

A firm draining-basin node or new dermal nodules between scar and nodal basin suggests regional spread and requires urgent oncology assessment.

Investigation priorities

01
Specialist dermoscopyFirst step

Identify melanoma-specific pigment, vascular, acral and nail structures and choose the biopsy plan.

Management branches

Suspicious primary lesionRefer intact for diagnosis

Clinical or dermoscopic features, evolution, nodular growth or acral or nail change raises melanoma concern.

  1. Make an urgent suspected-cancer referral with precise site, size, evolution and risk information and suitable consented images if locally supported.
  2. Leave the lesion intact for specialist dermoscopy and complete full-thickness excision biopsy unless an agreed expert pathway directs otherwise.
  3. Explain the difference between suspicion and diagnosis, track attendance and safety-net rapid change, bleeding or new nodes.
Open full textbook →Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG14 melanoma assessment and managementBiopsy, staging, excision, sentinel-node and follow-up recommendations.
  • NICE NG12 suspected skin cancer referralUrgent melanoma referral criteria.
  • NHS melanoma skin cancerSubtype recognition, diagnosis, treatment and surveillance.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom